Financial Results for the 3rd quarter of the year ending March 31, 2022

February 3, 2022
1. Financial results for the 3rd quarter of the year ending March 31, 2022

2. Forecast for the year ending March 31, 2022
### Summary for the 3rd quarter of the year ending March 31, 2022

#### Q3

<table>
<thead>
<tr>
<th>Actual</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue: ¥133.3B</td>
<td>Revenue: Down ¥17.3B</td>
</tr>
<tr>
<td>Operating Profit: ¥14.8B</td>
<td>Operating Profit: Surpassed by ¥4.9B</td>
</tr>
</tbody>
</table>

- Revenue down YoY for the company on the impact from decreased sales volumes due to parts procurement constraints in the Imaging Products Business and fewer sales of Semiconductor and FPD lithography systems in the Precision Equipment Business.

- Operating Profit up YoY for the company as profit growth in Imaging Products, Healthcare and Components Businesses overcame headwinds from reduced revenue in the Precision Equipment Business.

#### Q1-Q3

<table>
<thead>
<tr>
<th>Actual</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue: ¥406.3B</td>
<td>Revenue: Surpassed by ¥80.1B</td>
</tr>
<tr>
<td>Operating Profit: ¥46.9B</td>
<td>Operating Profit: Surpassed by ¥83.6B</td>
</tr>
</tbody>
</table>

Note: Amounts in this presentation material are rounded down to the hundred millions of yen.
3rd quarter of the year ending March 31, 2022: Financial Highlights

<table>
<thead>
<tr>
<th></th>
<th>FY2021/3 Q3 Actual (A)</th>
<th>FY2022/3 Q3 Actual (B)</th>
<th>Change (B)-(A)</th>
<th>FY2020/3 Q3 Actual (reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>150.6</td>
<td>133.3</td>
<td>-17.3</td>
<td>153.4</td>
</tr>
<tr>
<td><strong>Operating Profit</strong></td>
<td>9.9</td>
<td>14.8</td>
<td>+4.9</td>
<td>4.0</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>6.6%</td>
<td>11.1%</td>
<td></td>
<td>2.6%</td>
</tr>
<tr>
<td><strong>Profit before income taxes</strong></td>
<td>10.9</td>
<td>16.6</td>
<td>+5.7</td>
<td>5.8</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>7.2%</td>
<td>12.5%</td>
<td></td>
<td>3.8%</td>
</tr>
<tr>
<td><strong>Profit attributable to owners of the parent</strong></td>
<td>8.1</td>
<td>12.6</td>
<td>+4.5</td>
<td>3.9</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>5.4%</td>
<td>9.5%</td>
<td></td>
<td>2.5%</td>
</tr>
<tr>
<td><strong>FCF</strong></td>
<td>22.5</td>
<td>3.6</td>
<td>-18.9</td>
<td>0.8</td>
</tr>
<tr>
<td><strong>Exchange Rate:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US $</td>
<td>¥105</td>
<td>¥114</td>
<td>Impact on Revenue +6.2</td>
<td>¥109</td>
</tr>
<tr>
<td>EURO</td>
<td>¥125</td>
<td>¥130</td>
<td>Impact on Operating Profit +1.8</td>
<td>¥120</td>
</tr>
</tbody>
</table>

Operating profit margin improved thanks to a better breakeven point compared to FY2020/3 (before the COVID-19) and FY2021/3.
3rd quarter of the year ending March 31, 2022: Financial Highlights by Segments

<table>
<thead>
<tr>
<th>Billions of yen</th>
<th>FY2021/3 Q3 Actual (A)</th>
<th>FY2022/3 Q3 Actual (B)</th>
<th>Change (B)-(A)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imaging Products Business</strong></td>
<td>Revenue</td>
<td>52.4</td>
<td>46.8</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>-0.8</td>
<td>6.3</td>
</tr>
<tr>
<td><strong>Precision Equipment Business</strong></td>
<td>Revenue</td>
<td>66.6</td>
<td>43.7</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>11.4</td>
<td>3.1</td>
</tr>
<tr>
<td><strong>Healthcare Business</strong></td>
<td>Revenue</td>
<td>17.1</td>
<td>20.2</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>0.7</td>
<td>1.9</td>
</tr>
<tr>
<td><strong>Components Business</strong></td>
<td>Revenue</td>
<td>7.7</td>
<td>13.9</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>1.2</td>
<td>6.7</td>
</tr>
<tr>
<td><strong>Industrial Metrology and Others</strong></td>
<td>Revenue</td>
<td>6.9</td>
<td>8.9</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>0.5</td>
<td>1.7</td>
</tr>
<tr>
<td><strong>Corporate P/L non-attributable to any reportable segments</strong></td>
<td>Revenue</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>-3.5</td>
<td>-4.8</td>
</tr>
<tr>
<td><strong>Consolidated</strong></td>
<td>Revenue</td>
<td>150.6</td>
<td>133.3</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>9.9</td>
<td>14.8</td>
</tr>
</tbody>
</table>

Operating profit increased YoY in all segments except Precision Equipment Business. All segments were profitable.

Note: In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
### 1st to 3rd quarter of the year ending March 31, 2022: Financial Highlights

<table>
<thead>
<tr>
<th></th>
<th>FY2021/3 Q1-Q3 Actual (A)</th>
<th>FY2022/3 Q1-Q3 Actual (B)</th>
<th>Change (B)-(A)</th>
<th>FY2020/3 Q1-Q3 Actual (reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>326.2</td>
<td>406.3</td>
<td>+80.1</td>
<td>444.4</td>
</tr>
<tr>
<td><strong>Operating Profit</strong></td>
<td>-36.7</td>
<td>46.9</td>
<td>+83.6</td>
<td>21.5</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>-11.3%</td>
<td>11.5%</td>
<td></td>
<td>4.8%</td>
</tr>
<tr>
<td><strong>Profit before income taxes</strong></td>
<td>-27.9</td>
<td>52.5</td>
<td>+80.4</td>
<td>25.9</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>-8.6%</td>
<td>12.9%</td>
<td></td>
<td>5.8%</td>
</tr>
<tr>
<td><strong>Profit attributable to owners of the parent</strong></td>
<td>-23.4</td>
<td>39.0</td>
<td>+62.4</td>
<td>20.2</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>-7.2%</td>
<td>9.6%</td>
<td></td>
<td>4.5%</td>
</tr>
<tr>
<td><strong>FCF</strong></td>
<td>10.4</td>
<td>24.4</td>
<td>+14.0</td>
<td>4.7</td>
</tr>
<tr>
<td><strong>Exchange Rate:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US$</td>
<td>¥106</td>
<td>¥111</td>
<td>+14.6</td>
<td>¥109</td>
</tr>
<tr>
<td>EURO</td>
<td>¥122</td>
<td>¥131</td>
<td>+4.6</td>
<td>¥121</td>
</tr>
</tbody>
</table>

**Impact on Revenue:** ¥109

**Impact on Operating Profit:** ¥121
1st to 3rd quarter of the year ending March 31, 2022: Financial Highlights by Segments

<table>
<thead>
<tr>
<th>Billions of yen</th>
<th>FY2021/3 Q1-Q3</th>
<th>FY2022/3 Q1-Q3</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Actual (A)</td>
<td>Actual (B)</td>
<td>(B)-(A)</td>
</tr>
<tr>
<td>Imaging Products Business</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>116.7</td>
<td>136.0</td>
<td>+16.5%</td>
</tr>
<tr>
<td>Operating profit</td>
<td>-28.6</td>
<td>18.8</td>
<td>+¥47.4B</td>
</tr>
<tr>
<td>Precision Equipment Business</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>130.4</td>
<td>162.9</td>
<td>+24.9%</td>
</tr>
<tr>
<td>Operating profit</td>
<td>4.0</td>
<td>24.8</td>
<td>+¥20.8B</td>
</tr>
<tr>
<td>Healthcare Business</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>42.8</td>
<td>53.2</td>
<td>+24.3%</td>
</tr>
<tr>
<td>Operating profit</td>
<td>-1.6</td>
<td>2.8</td>
<td>+¥4.4B</td>
</tr>
<tr>
<td>Components Business</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>18.1</td>
<td>30.6</td>
<td>+69.1%</td>
</tr>
<tr>
<td>Operating profit</td>
<td>0.3</td>
<td>10.1</td>
<td>+¥9.8B</td>
</tr>
<tr>
<td>Industrial Metrology and Others</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>18.1</td>
<td>23.5</td>
<td>+29.8%</td>
</tr>
<tr>
<td>Operating profit</td>
<td>0.0</td>
<td>0.1</td>
<td>+¥0.1B</td>
</tr>
<tr>
<td>Corporate P/L non-attributable to any reportable segments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Operating profit</td>
<td>-10.9</td>
<td>-9.8</td>
<td>+¥1.1B</td>
</tr>
<tr>
<td>Consolidated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>326.2</td>
<td>406.3</td>
<td>+24.6%</td>
</tr>
<tr>
<td>Operating profit</td>
<td>-36.7</td>
<td>46.9</td>
<td>+¥83.6B</td>
</tr>
</tbody>
</table>

Revenue and operating profit increased YoY in all segments and became profitable.

Note: In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
### 3rd quarter of the year ending March 31, 2022: Imaging Products Business

<table>
<thead>
<tr>
<th></th>
<th>FY2021/3 Actual</th>
<th>FY2022/3 Actual</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q3 (A)</td>
<td>Q1-Q3 (B)</td>
<td>Q3 (C)</td>
</tr>
<tr>
<td>Revenue (Billions of yen)</td>
<td>52.4</td>
<td>116.7</td>
<td>46.8</td>
</tr>
<tr>
<td>Operating Profit (%) vs Revenue</td>
<td>-0.8</td>
<td>-28.6</td>
<td>6.3</td>
</tr>
<tr>
<td>Digital Camera-Interchangeable Lens type</td>
<td>280 (Units sold: 1,000)</td>
<td>660</td>
<td>160</td>
</tr>
<tr>
<td>Interchangeable Lens (Units sold: 1,000)</td>
<td>470</td>
<td>1,080</td>
<td>360</td>
</tr>
<tr>
<td>Compact DSC (Units sold: 1,000)</td>
<td>80</td>
<td>200</td>
<td>40</td>
</tr>
</tbody>
</table>

**Q3 YoY Change:** Due to parts procurement constraints, sales volumes decreased. Mirrorless volumes beat DSLR in both camera bodies and interchangeable lenses. Averaging sales price(ASP) increased as the shift to models for pro/hobbyist progresses, with a boost from the flagship model Z9 newly released in December. Revenue decreased in lower sales volumes despite of increased ASP. Operating profit grew on increased ASP and benefits from reduced business costs.

---

Note: In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
3rd quarter of the year ending March 31, 2022: Precision Equipment Business

<table>
<thead>
<tr>
<th></th>
<th>FY2021/3 Actual</th>
<th>FY2022/3 Actual</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 (A) Q1-Q3 (B)</td>
<td>Q3 (C) Q1-Q3 (D)</td>
<td>(C)-(A)</td>
<td>(D)-(B)</td>
</tr>
<tr>
<td>Revenue</td>
<td>66.6 130.4</td>
<td>43.7 162.9</td>
<td>-22.9</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>11.4 4.0</td>
<td>3.1 24.8</td>
<td>-8.3</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>17.1% 3.1%</td>
<td>7.1% 15.2%</td>
<td></td>
</tr>
<tr>
<td>FPD Lithography Systems</td>
<td>12 17</td>
<td>7 37</td>
<td>-5</td>
</tr>
<tr>
<td>(units)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Semiconductor Lithography</td>
<td>5/2 11/5</td>
<td>3/5 4/14</td>
<td>-2/+3</td>
</tr>
<tr>
<td>Systems New/Refurbished</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(units)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Q3 YoY Change:** Revenue and operating profit were down. The service business trended well in both FPD and Semiconductor Lithography Businesses. However, sales volumes decreased in FPD lithography systems for large panels and new semiconductor lithography systems.

Note: In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
3rd quarter of the year ending March 31, 2022: Healthcare Business

<table>
<thead>
<tr>
<th></th>
<th>FY2021/3 Actual</th>
<th>FY2022/3 Actual</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q3 (A)</td>
<td>Q1-Q3 (B)</td>
<td>(C)-(A)</td>
</tr>
<tr>
<td>Revenue</td>
<td>17.1</td>
<td>42.8</td>
<td>+3.1</td>
</tr>
<tr>
<td>Operating</td>
<td>0.7</td>
<td>-1.6</td>
<td>+1.2</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>4.1%</td>
<td>-3.7%</td>
<td>9.4%</td>
</tr>
</tbody>
</table>

**Q3 YoY Change:** Revenue and operating profit for the whole business trended well primarily in North America and Europe in both biological microscopes and retinal diagnostic imaging systems. Operating profit hit a quarterly record high.
3rd quarter of the year ending March 31, 2022:
Components Business

<table>
<thead>
<tr>
<th></th>
<th>FY2021/3 Actual</th>
<th>FY2022/3 Actual</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q3 (A)</td>
<td>Q1-Q3 (B)</td>
<td>(C)-(A)</td>
</tr>
<tr>
<td>Revenue</td>
<td>7.7</td>
<td>18.1</td>
<td>+6.2</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>1.2</td>
<td>0.3</td>
<td>+5.5</td>
</tr>
</tbody>
</table>

|                    | % vs Revenue    |                |        |        |
|--------------------|-----------------|----------------|--------|
| Revenue            | 15.6%           |                |        |        |
| Operating Profit   | 1.7%            |                |        |        |

Q3 YoY Change: Revenue and operating profit grew. EUV related components made significant contributions to growth in sales and profit. Additionally, sales were strong in optical parts for semiconductor related products, encoders for industrial equipment and photomask substrates for FPD.

Note: In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
### Q3 YoY Change:

In the Industrial Metrology Business, revenue and operating profit grew on sustained activity in semiconductors and electronic components while imaging metrology equipment and industrial microscopes drove sales.

---

Note: In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
1. Financial results for the 3rd quarter of the year ending March 31, 2022

2. Forecast for the year ending March 31, 2022
Forecast for the year ending March 31, 2022

**Revenue**

- **Company total forecast: ¥550.0B** (Revised upward ¥15.0B vs. previous forecast)
  - Imaging Products: Revised upward ¥5.0B, reflecting improvement of sales mix and impact of foreign exchange, etc.
  - Precision Equipment: Revised upward ¥3.0B, reflecting increased service revenue and impact of foreign exchange, etc.
  - Components: Revised upward ¥4.0B, expecting increase in sales of EUV related component, optical parts and encoders.

**Operating profit**

- **Company total forecast: ¥47.0B** (Revised upward ¥13.0B vs. previous forecast)
  - Imaging Products: Revised upward ¥5.0B, reflecting improvement of revenue and expense control, etc.
  - Precision Equipment: Revised upward ¥2.5B, reflecting improvement of revenue and expense control, etc.
  - Healthcare: Revised upward ¥1.5B, reflecting improvement of revenue and expense control, etc.
  - Components: Revised upward ¥4.0B, reflecting improvement of revenue and expense control, etc.

**Profit attributable to owners of the parent**

- **Company total forecast: ¥39.0B** (Revised upward ¥10.0B vs. previous forecast)

**Shareholder Returns**

- **Annual Dividend: ¥40, Interim Dividend: ¥20** (unchanged from previous forecast)
Forecast for the year ending March 31, 2022:
Operating Profit Breakdown

Significant upwards of operating profit, because of foreign exchange impact, increased sales and expense control, etc.

Note: U.S. Pension Fund: Posted one-time profit in 1H of FY2022/3 due to changes in pension system at US subsidiary. In 2H of FY2022/3, an approximately equivalent amount in costs was expected to detract from operating profit, however, some of the costs were booked directly as equity, other comprehensive income, without hitting the income statement, and the operating profit upwards vs. previous forecast.
Forecast for the year ending March 31, 2022: Financial Highlights

<table>
<thead>
<tr>
<th>Billions of yen</th>
<th>FY2021/3 Actual (A)</th>
<th>Previous Forecast (Nov. 4) (B)</th>
<th>New Forecast (Feb. 3) (C)</th>
<th>Change (C)-(A)</th>
<th>Change (C)-(B)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>451.2</td>
<td>535.0</td>
<td><strong>550.0</strong></td>
<td>+98.8</td>
<td>+15.0</td>
</tr>
<tr>
<td><strong>Operating Profit</strong></td>
<td>-56.2</td>
<td>34.0</td>
<td><strong>47.0</strong></td>
<td>+103.2</td>
<td>+13.0</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>-12.5%</td>
<td>6.4%</td>
<td><strong>8.5%</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Profit before income taxes</strong></td>
<td>-45.3</td>
<td>39.0</td>
<td><strong>53.0</strong></td>
<td>+98.3</td>
<td>+14.0</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>-10.0%</td>
<td>7.3%</td>
<td><strong>9.6%</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Profit attributable to owners of the parent</strong></td>
<td>-34.4</td>
<td>29.0</td>
<td><strong>39.0</strong></td>
<td>+73.4</td>
<td>+10.0</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>-7.6%</td>
<td>5.4%</td>
<td><strong>7.1%</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS</strong></td>
<td>¥-93.96</td>
<td>¥78.98</td>
<td><strong>¥106.21</strong></td>
<td>+¥200.17</td>
<td>+¥27.23</td>
</tr>
<tr>
<td><strong>Annual Dividends</strong></td>
<td>¥20</td>
<td>¥40</td>
<td>¥40</td>
<td>+¥20</td>
<td>±0</td>
</tr>
<tr>
<td><strong>Exchange Rate:</strong></td>
<td><strong>US $</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>¥106</td>
<td>¥107</td>
<td><strong>¥112</strong></td>
<td>+¥19.1</td>
<td>+¥10.6</td>
</tr>
<tr>
<td></td>
<td><strong>EURO</strong></td>
<td></td>
<td></td>
<td>+¥5.6</td>
<td>+¥2.6</td>
</tr>
</tbody>
</table>

Note: EPS (Basic Earning per Share) = Profit attributable to owner of the parent / Average number of shares during the term
Approx. 0.367B shares, an average over the number of shares at the end of FY2021/3 and the expected number of shares at the end of FY2022/3.
Forecast for the year ending March 31, 2022: Operating Profit History last 10 years

Operating profit in FY2022/3 is projected to recover to average level before the COVID-19

Note: Adopted Japanese standard until FY2015/3.
Forecast for the year ending March 31, 2022: Financial Highlights by Segments

<table>
<thead>
<tr>
<th>Bills of yen</th>
<th>FY2021/3 Actual (A)</th>
<th>Previous Forecast (Nov.4) (B)</th>
<th>New Forecast (Feb.3) (C)</th>
<th>Change (C)-(A)</th>
<th>Change (C)-(B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging Products Business</td>
<td>Revenue 150.2</td>
<td>Operating Profit -36.3 (- 33.0)</td>
<td>175.0 15.0</td>
<td>180.0</td>
<td>+19.8%</td>
</tr>
<tr>
<td>Precision Equipment Business</td>
<td>Revenue 184.7</td>
<td>Operating Profit -0.6 (- 0.6)</td>
<td>217.0 23.0</td>
<td>220.0</td>
<td>+19.1%</td>
</tr>
<tr>
<td>Healthcare Business</td>
<td>Revenue 62.8</td>
<td>Operating Profit -3.0 (- 3.0)</td>
<td>70.0 2.0</td>
<td>73.0</td>
<td>+16.2%</td>
</tr>
<tr>
<td>Components Business</td>
<td>Revenue 25.7</td>
<td>Operating Profit 0.1 (0.1)</td>
<td>38.0 8.5</td>
<td>42.0</td>
<td>+63.4%</td>
</tr>
<tr>
<td>Industrial Metrology and Others</td>
<td>Revenue 27.6</td>
<td>Operating Profit -1.2 (- 0.3)</td>
<td>35.0 1.5</td>
<td>35.0</td>
<td>+26.8%</td>
</tr>
<tr>
<td>Corporate P/L non-attributable to any reportable segments</td>
<td>Revenue</td>
<td>Operating Profit -15.0 (- 15.0)</td>
<td>-16.0</td>
<td>-16.0</td>
<td>-1.0B</td>
</tr>
<tr>
<td>Consolidated</td>
<td>Revenue 451.2</td>
<td>Operating Profit -56.2 (- 51.9)</td>
<td>535.0 34.0</td>
<td>550.0</td>
<td>+21.9%</td>
</tr>
</tbody>
</table>

Note: OP figures in parentheses are the operating profit excluding restructuring relevant expenses.

In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
## Forecast for the year ending March 31, 2022:
### Imaging Products Business

<table>
<thead>
<tr>
<th></th>
<th>FY21/3 Actual</th>
<th>FY22/3 Forecast (Nov. 4)</th>
<th>FY22/3 Forecast (Feb. 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digital Camera-Interchangeable Lens type (units:1,000)</td>
<td>150.2</td>
<td>175.0</td>
<td>180.0</td>
</tr>
<tr>
<td>Market Scale</td>
<td>5,520</td>
<td>5,400</td>
<td>5,200</td>
</tr>
<tr>
<td>Nikon</td>
<td>840</td>
<td>750</td>
<td>700</td>
</tr>
<tr>
<td><strong>Interchangeable Lens (units:1,000)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Market Scale</td>
<td>9,110</td>
<td>9,200</td>
<td>9,200</td>
</tr>
<tr>
<td>Nikon</td>
<td>1,350</td>
<td>1,300</td>
<td>1,300</td>
</tr>
<tr>
<td><strong>Compact DSC (units:1,000)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Market Scale</td>
<td>3,430</td>
<td>2,850</td>
<td>2,850</td>
</tr>
<tr>
<td>Nikon</td>
<td>260</td>
<td>200</td>
<td>200</td>
</tr>
</tbody>
</table>

### Operating Profit: Revised upward ¥56.3B YoY
(Up ¥5.0B vs. previous forecast)
- Restructuring efforts will continue through the end of the fiscal year, achieving a cumulative ¥63.0B reduction in business costs over the three years of the medium-term management plan.
- Q4 operating profit is projected to decline QoQ due to a concentration of costs related to new products.
- Full-year operating profit should beat our previous forecast, bringing the OP margin above 10%, thanks to FX impact and product mix improvements.

### Revenue: Revised upward ¥29.8B YoY
(Up ¥5.0B vs. previous forecast)
- Projecting lower sales volumes both in the market and at Nikon due to parts procurement constraints.
- Strong advance orders and sales of the flagship model Z 9. Also, expansion of lineup of Z-mount lenses is fulfilling demand from pro/hobbyist.
- Revised upward on higher ASP driven by foreign exchange (FX) assumption changes and improved product mix.
- Even as we focus on address parts procurement constraints, we expect to be impacted into next fiscal year.

---

**Note:** In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
Forecast for the year ending March 31, 2022:
Precision Equipment Business

- **Revenue: Revised upward ¥35.3B YoY**
  (Up ¥3.0B vs. previous forecast)
  - Sales of FPD and Semiconductor lithography systems in line with plan.
  - The service business is trending well.

- **Operating Profit: Revised upward ¥26.1B YoY**
  (Up ¥2.5B vs. previous forecast)
  - Revising guidance upward ¥2.5B vs. previous forecast due to factors including strength in the service business for FPD and Semiconductor and expense control.

### FPD Lithography Systems (units)

<table>
<thead>
<tr>
<th>Market Scale (CY19/20)</th>
<th>FY21/3 Actual</th>
<th>FY22/3 Forecast (Nov. 4)</th>
<th>FY22/3 Forecast (Feb. 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FPD Lithography Systems (units)</td>
<td>184.7</td>
<td>217.0</td>
<td>220.0</td>
</tr>
</tbody>
</table>

### Semiconductor Lithography Systems (New/Refurbished, units)

<table>
<thead>
<tr>
<th>Market Scale (CY19/20)</th>
<th>FY21/3 Actual</th>
<th>FY22/3 Forecast (Nov. 4)</th>
<th>FY22/3 Forecast (Feb. 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nikon</td>
<td>29</td>
<td>46</td>
<td>46</td>
</tr>
</tbody>
</table>

Note: In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
Forecast for the year ending March 31, 2022: Healthcare Business

- **Revenue: Revise upward ¥10.2B YoY (Up ¥3.0B vs. previous forecast)**
  - Business has been good, thanks to strong demand for biological microscopes and better-than-expected performance in retinal diagnostic imaging systems.

- **Operating Profit: Revised upward ¥6.5B YoY (Up ¥1.5B vs. previous forecast)**
  - Revised upward ¥1.5B vs. previous forecast reflect benefits from increased revenue and expense control.
### Forecast for the year ending March 31, 2022: Components Business

<table>
<thead>
<tr>
<th></th>
<th>FY21/3 Actual</th>
<th>FY22/3 Forecast (Nov. 4)</th>
<th>FY22/3 Forecast (Feb. 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>25.7</td>
<td>38.0</td>
<td>42.0</td>
</tr>
<tr>
<td>Operating profit</td>
<td>0.1</td>
<td>8.5</td>
<td>12.5</td>
</tr>
</tbody>
</table>

#### Revenue: Revised upward ¥16.3B YoY (Up ¥4.0B vs. previous forecast)
- Sales of EUV related component forecasting to increase.
- Upward vs. previous forecast because optical parts for semiconductor related products and encoders for industrial equipment, etc. are trending well.

#### Operating profit: Revised upward ¥12.4B YoY (Up ¥4.0B vs. previous forecast)
- Revised upward ¥4.0B vs. previous forecast to reflect benefits from increased revenue and expense control.

Note: Actual in FY2021/3 and comments referring previous year are reference, as new disclosure.

In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
Forecast for the year ending March 31, 2022:
Industrial Metrology Business and Others

- **Revenue: Up ￥7.4B YoY**
  - In the Industrial Metrology Business, revenue growth YoY on sustained strength in demand for metrology equipment and microscopes.

- **Operating Profit: Up ￥2.7B YoY**
  - Profit growth YoY to reflect to benefits from increased revenue and expense control.

Note: In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
Reference Data
## Business segments and major products

<table>
<thead>
<tr>
<th>Segments</th>
<th>Description</th>
<th>Major products</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imaging Products Business</strong></td>
<td>Digital camera-interchangeable lens type&lt;br&gt;Interchangeable lens&lt;br&gt;Compact camera</td>
<td>Mirrorless Camera [Z 9]&lt;br&gt;Mirrorless Camera [Z fc]&lt;br&gt;NIROR Lens&lt;br&gt;[NIKKOR Z 70-200mm f/2.8 VR S]</td>
<td></td>
</tr>
<tr>
<td><strong>Precision Equipment Business</strong></td>
<td>FPD lithography system&lt;br&gt;Semiconductor lithography system&lt;br&gt;Alignment Station&lt;br&gt;Measuring &amp; inspection systems</td>
<td>FPD Scanner [FX-1636/SH]&lt;br&gt;ArF Immersion Scanner [NSR-S635E]&lt;br&gt;Alignment Station [Litho Booster]&lt;br&gt;Automatic Macro Inspection System [AMI-5700]</td>
<td></td>
</tr>
<tr>
<td><strong>Components Business</strong></td>
<td>EUV related component&lt;br&gt;Optical components, Optical parts&lt;br&gt;Encoders and Actuators&lt;br&gt;Photomask substrate for FPD&lt;br&gt;Optical processing machine and Contract material processing</td>
<td>Optical Components&lt;br&gt;Intelligent actuator units [C3 eMotion]&lt;br&gt;Photomask Substrates for FPD&lt;br&gt;Optical Processing Machine [Lasermeister102A]</td>
<td></td>
</tr>
<tr>
<td><strong>Industrial Metrology and Others</strong></td>
<td>Measuring instrument&lt;br&gt;X-ray and CT inspection system&lt;br&gt;Industrial Microscope</td>
<td>CNC Video Measuring System [NEXIV VM2-S Series]&lt;br&gt;X-ray and CT Inspection [XT H 225 ST 2x]&lt;br&gt;Non-Contact Large Volume Inspection System [APDIS]</td>
<td></td>
</tr>
</tbody>
</table>
## Forecast for the year ending March 31, 2022: Financial Highlights (Half year/Full year)

<table>
<thead>
<tr>
<th></th>
<th>FY2019/3</th>
<th>FY2020/3</th>
<th>FY2021/3</th>
<th>FY2022/3 (Forecast)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1H</td>
<td>2H</td>
</tr>
<tr>
<td><strong>Billions of yen</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>708.6</td>
<td>591.0</td>
<td>175.6</td>
<td>275.6</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>82.6</td>
<td>6.7</td>
<td>-46.6</td>
<td>-9.6</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>11.7%</td>
<td>1.1%</td>
<td>-26.5%</td>
<td>-3.5%</td>
</tr>
<tr>
<td>Profit before income taxes</td>
<td>87.9</td>
<td>11.8</td>
<td>-38.8</td>
<td>-6.5</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>12.4%</td>
<td>2.0%</td>
<td>-22.1%</td>
<td>-2.4%</td>
</tr>
<tr>
<td>Profit attributable to owners of the parent</td>
<td>66.5</td>
<td>7.6</td>
<td>-31.5</td>
<td>-2.9</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>9.4%</td>
<td>1.3%</td>
<td>-17.9%</td>
<td>-1.1%</td>
</tr>
<tr>
<td>EPS</td>
<td>¥167.86</td>
<td>¥19.93</td>
<td>-¥93.96</td>
<td></td>
</tr>
<tr>
<td>Annual Dividends</td>
<td>¥60</td>
<td>¥40</td>
<td>¥20</td>
<td></td>
</tr>
<tr>
<td>ROE</td>
<td>11.2%</td>
<td>1.3%</td>
<td>-6.4%</td>
<td></td>
</tr>
<tr>
<td>FCF</td>
<td>43.5</td>
<td>-4.8</td>
<td>22.9</td>
<td></td>
</tr>
<tr>
<td>Exchange Rate : US $</td>
<td>¥111</td>
<td>¥109</td>
<td>¥107</td>
<td>¥105</td>
</tr>
<tr>
<td>EURO</td>
<td>¥128</td>
<td>¥121</td>
<td>¥121</td>
<td>¥126</td>
</tr>
</tbody>
</table>

**Exchange Rate:**
- US $: ¥110, ¥114, ¥112
- EURO: ¥131, ¥130, ¥130
## Forecast for the year ending March 31, 2022: Financial Highlights by Segments (Half year/Full year)

### Billions of yen

<table>
<thead>
<tr>
<th>Segment</th>
<th>FY2019/3</th>
<th>FY2020/3</th>
<th>FY2021/3</th>
<th>FY2022/3 (Forecast)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Full year</td>
<td>Full year</td>
<td>1H</td>
<td>2H</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1H</td>
<td>2H</td>
</tr>
<tr>
<td><strong>Imaging Products Business</strong></td>
<td>Revenue</td>
<td>296.1</td>
<td>225.8</td>
<td>64.3</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>22.0</td>
<td>(-17.1)</td>
<td>(-26.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(22.6)</td>
<td>(- 14.4)</td>
<td>(- 6.3)</td>
</tr>
<tr>
<td><strong>Precision Equipment Business</strong></td>
<td>Revenue</td>
<td>274.5</td>
<td>245.0</td>
<td>63.8</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>81.7</td>
<td>48.0</td>
<td>(-7.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(81.7)</td>
<td>(48.0)</td>
<td>(6.8)</td>
</tr>
<tr>
<td><strong>Healthcare Business</strong></td>
<td>Revenue</td>
<td>65.4</td>
<td>62.0</td>
<td>25.7</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>-1.9</td>
<td>-2.4</td>
<td>(-2.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(-1.9)</td>
<td>(-2.4)</td>
<td>(-3.0)</td>
</tr>
<tr>
<td><strong>Components Business</strong></td>
<td>Revenue</td>
<td>72.5</td>
<td>58.0</td>
<td>11.2</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>6.9</td>
<td>1.8</td>
<td>(-0.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(7.5)</td>
<td>(1.8)</td>
<td>(0.1)</td>
</tr>
<tr>
<td><strong>Industrial Metrology and Others</strong></td>
<td>Revenue</td>
<td>708.6</td>
<td>591.0</td>
<td>175.6</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>82.6</td>
<td>6.7</td>
<td>(-46.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(84.4)</td>
<td>(11.2)</td>
<td>(-45.3)</td>
</tr>
<tr>
<td><strong>Corporate P/L non-attributable to any reportable segments</strong></td>
<td>Revenue</td>
<td>-26.1</td>
<td>-23.6</td>
<td>-7.4</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>(-25.6)</td>
<td>(-21.9)</td>
<td>(-7.4)</td>
</tr>
<tr>
<td><strong>Consolidated</strong></td>
<td>Revenue</td>
<td>723.0</td>
<td>277.0</td>
<td>451.2</td>
</tr>
<tr>
<td></td>
<td>Operating Profit</td>
<td>32.1</td>
<td>14.9</td>
<td>14.9</td>
</tr>
</tbody>
</table>

Note: Figures in parentheticals for operating profit exclude restructuring relevant expenses.

In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
# Financial Highlights by Segment

3rd quarter of the year ending March 31, 2022:

<table>
<thead>
<tr>
<th>Billions of yen</th>
<th>FY2021/3</th>
<th>FY2022/3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1</td>
<td>Q2</td>
</tr>
<tr>
<td><strong>Imaging Products Business</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>25.1</td>
<td>39.2</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>-8.3</td>
<td>-19.5</td>
</tr>
<tr>
<td><strong>Precision Equipment Business</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>19.6</td>
<td>44.2</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>-5.7</td>
<td>-1.7</td>
</tr>
<tr>
<td><strong>Healthcare Business</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>10.3</td>
<td>15.4</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>-2.4</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Components Business</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>4.6</td>
<td>5.8</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>-0.3</td>
<td>-0.6</td>
</tr>
<tr>
<td><strong>Industrial Metrology and Others</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>4.9</td>
<td>6.3</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>0.9</td>
<td>-1.4</td>
</tr>
<tr>
<td><strong>Corporate P/L non-attributable to any reportable segments</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>-4.6</td>
<td>-2.8</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>(-4.6)</td>
<td>(-2.8)</td>
</tr>
<tr>
<td><strong>Consolidated</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>64.7</td>
<td>110.9</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>-20.5</td>
<td>-26.1</td>
</tr>
</tbody>
</table>

Note: Figures in parentheticals for operating profit exclude restructuring relevant expenses.

In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.
### 3rd quarter of the year ending March 31, 2022: Financial Position Breakdown

#### ASSETS

<table>
<thead>
<tr>
<th></th>
<th>20/12</th>
<th>21/3</th>
<th>21/12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; Cash Equivalents</td>
<td>342.3</td>
<td>351.7</td>
<td>367.3</td>
</tr>
<tr>
<td>Trade &amp; other receivables</td>
<td>78.7</td>
<td>72.9</td>
<td>80.4</td>
</tr>
<tr>
<td>Inventories</td>
<td>245.1</td>
<td>235.7</td>
<td>232.3</td>
</tr>
<tr>
<td>Other current financial /current assets</td>
<td>16.6</td>
<td>15.6</td>
<td>12.5</td>
</tr>
<tr>
<td>Non-current assets</td>
<td>338.3</td>
<td>313.8</td>
<td>328.8</td>
</tr>
</tbody>
</table>

#### LIABILITIES/ EQUITY

<table>
<thead>
<tr>
<th></th>
<th>20/12</th>
<th>21/3</th>
<th>21/12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advances received</td>
<td>181.4</td>
<td>163.1</td>
<td>129.4</td>
</tr>
<tr>
<td>Interest-bearing debt</td>
<td>156.5</td>
<td>147.6</td>
<td>161.7</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>138.6</td>
<td>140.3</td>
<td>144.1</td>
</tr>
<tr>
<td>Total equity</td>
<td>544.5</td>
<td>538.7</td>
<td>586.1</td>
</tr>
</tbody>
</table>

#### Equity ratio

<table>
<thead>
<tr>
<th></th>
<th>20/12</th>
<th>21/3</th>
<th>21/12</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>53.2%</td>
<td>54.3%</td>
<td>57.2%</td>
</tr>
</tbody>
</table>

Note: Equity ratio is ratio of equity attributable to owners of the parent to total assets. Cash and Cash Equivalents excludes time deposits with maturities of three months or more.
Forecast for the year ending March 31, 2022: Capital Expenditures, Depreciation and Inventory

Note: Capital expenditures in FY2020/3 include the ¥4.0B of leased assets upon the adoption of IFRS16. For the FY2022/3, the asset recording of rents in the head office building is included. Depreciation from FY2018/3 includes the amortization of capitalized R&D costs and form FY2020/3 includes leased assets, same as capital expenditures. The Semiconductor Related Equipment Business, which had belonged to Industrial Metrology and Others, has been transferred to the Precision Equipment Business. Inventory of ¥3.7B in the end of FY2020/3 and ¥2.4B in the end of FY2021/3 have been transferred from Industrial Metrology and Others to the Precision Equipment Business as a result of retroactive application to the end of FY2021/3, respectively.
1st to 3rd quarter of the year ending March 31, 2022: Revenue Breakdown

### BY SEGMENT

- Industrial Metrology and Others
  - 33% of total: ¥136.0 billion
  - 22/3% of total: ¥65.3 billion
- Healthcare
  - 13% of total: ¥53.2 billion
  - 21/3% of total: ¥42.8 billion
- Components
  - 6% of total: ¥23.5 billion
  - 22/3% of total: ¥18.1 billion
- Imaging Products
  - 40% of total: ¥116.7 billion
  - 22/3% of total: ¥49.7 billion
- Precision Equipment
  - 40% of total: ¥162.9 billion
  - 22/3% of total: ¥52.2 billion

### BY REGION

- Japan
  - 16% of total: ¥66.7 billion
  - 22/3% of total: ¥51.3 billion
- United States
  - 24% of total: ¥95.7 billion
  - 22/3% of total: ¥88.1 billion
- Europe
  - 13% of total: ¥53.5 billion
  - 22/3% of total: ¥49.7 billion
- China
  - 31% of total: ¥125.1 billion
  - 22/3% of total: ¥84.9 billion
- Others
  - 16% of total: ¥65.3 billion
  - 22/3% of total: ¥49.7 billion

Note: The outside and inside circles show the breakdown of FY2022/3 Q1-Q3 revenue of ¥406.3B and FY2021/3 Q1-Q3 revenue of ¥326.2B, respectively.
Note: R&D expenditures after FY2018/3 includes capitalization of some development expenditure.
Cash Flow History

Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents.
Imaging Products Business: Sales Units

SALES IN UNITS BY PRODUCT CATEGORY

DCIL (Digital Camera-Interchangeable Lens Type)  | Interchangeable Lens  | CDSC (Compact Digital Still Camera)

1,500K Units

1,000

700

500

300

100

0
Forecast for the year ending March 31, 2022: Precision Equipment Business Sales Units

FPD LITHOGRAPHY SYSTEMS SALES BY GENERATION

<table>
<thead>
<tr>
<th></th>
<th>18/3 Actual</th>
<th>19/3 Actual</th>
<th>20/3 Actual</th>
<th>21/3 Actual</th>
<th>Forecast (Nov. 4)</th>
<th>Forecast (Feb. 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>G5/6</td>
<td>34</td>
<td>16</td>
<td>5</td>
<td>11</td>
<td>30</td>
<td>46</td>
</tr>
<tr>
<td>G7/8</td>
<td>17</td>
<td>27</td>
<td>14</td>
<td>30</td>
<td>46</td>
<td>15</td>
</tr>
<tr>
<td>G10.5</td>
<td>30</td>
<td>29</td>
<td>15</td>
<td>15</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)

<table>
<thead>
<tr>
<th></th>
<th>18/3 Actual</th>
<th>19/3 Actual</th>
<th>20/3 Actual</th>
<th>21/3 Actual</th>
<th>Forecast (Nov. 4)</th>
<th>Forecast (Feb. 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ArF immersion</td>
<td>30</td>
<td>8</td>
<td>14</td>
<td>12</td>
<td>18</td>
<td>14</td>
</tr>
<tr>
<td>ArF</td>
<td>12</td>
<td>3</td>
<td>4</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KrF</td>
<td>12</td>
<td>3</td>
<td>4</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>i-line</td>
<td>12</td>
<td>3</td>
<td>4</td>
<td>8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: The unit sales of new semiconductor lithography systems is 17 units in FY2018/3, 21 units in FY2019/3, 34 units in FY2020/3, 16 units in FY2021/3 and 12 units (forecast) in FY2022/3.
## Precision Equipment Business: Sales Units

### FPD Lithography Systems Sales in Units by Generation

<table>
<thead>
<tr>
<th>Quarter</th>
<th>G5/6</th>
<th>G7/8</th>
<th>G10.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>19/3-Q1</td>
<td>17</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>19/3-Q2</td>
<td>13</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>19/3-Q3</td>
<td>11</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>19/3-Q4</td>
<td>12</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>20/3-Q1</td>
<td>13</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>20/3-Q2</td>
<td>17</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>20/3-Q3</td>
<td>16</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>20/3-Q4</td>
<td>16</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>21/3-Q1</td>
<td>12</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>21/3-Q2</td>
<td>12</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>21/3-Q3</td>
<td>6</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>22/3-Q1</td>
<td>13</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>22/3-Q2</td>
<td>13</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>22/3-Q3</td>
<td>10</td>
<td>7</td>
<td>1</td>
</tr>
</tbody>
</table>
### Precision Equipment Business: Sales Units

#### SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES

**IN UNITS** **BY TECHNOLOGY (INCL. REFURBISHED)**

<table>
<thead>
<tr>
<th>Period</th>
<th>i-line</th>
<th>KrF</th>
<th>ArF</th>
<th>ArF immersion</th>
</tr>
</thead>
<tbody>
<tr>
<td>18/3-Q1</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>18/3-Q2</td>
<td>6</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>18/3-Q3</td>
<td>6</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>19/3-Q1</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>19/3-Q2</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>19/3-Q3</td>
<td>7</td>
<td>4</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>19/3-Q4</td>
<td>10</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>20/3-Q1</td>
<td>18</td>
<td>4</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>20/3-Q2</td>
<td>11</td>
<td>3</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>20/3-Q3</td>
<td>10</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>20/3-Q4</td>
<td>17</td>
<td>5</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>21/3-Q1</td>
<td>11</td>
<td>2</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>21/3-Q2</td>
<td>6</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>21/3-Q3</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>21/3-Q4</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>22/3-Q1</td>
<td>9</td>
<td>1</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>22/3-Q2</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>22/3-Q3</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>5</td>
</tr>
</tbody>
</table>

*Note: Numbers indicate units sold.*
Forecast for the year ending March 31, 2022: Foreign Exchange Impact

<table>
<thead>
<tr>
<th>Exchange Rate</th>
<th>Financial Impact from Fluctuation by 1 yen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FY2022/3 Forecast for Q4</td>
</tr>
<tr>
<td>US $</td>
<td>¥115</td>
</tr>
<tr>
<td>EURO</td>
<td>¥130</td>
</tr>
</tbody>
</table>

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US$ and Euro.
Sustainability strategy based on corporate philosophy of “Trustworthiness and Creativity”

Redisplaying of Financial Results for the 2nd quarter of the year ending March 31, 2022

12 Materialities (CSR Priority Issues)

1. Creating social value through core technologies
2. Ensuring trustworthiness by maintaining and increasing quality
3. Promoting a decarbonized society
4. Promoting resource circulation
5. Preventing pollution and conserving ecosystems
6. Strengthening supply chain management
7. Respecting human rights
8. Diversity and inclusion
9. Employees’ health and safety
10. Thorough compliance
11. Strengthening corporate governance
12. Strengthening risk management

1. Creating social value through core technologies: Contributing to a sustainable society through Nikon’s unique technology in growth areas in addition to existing businesses

- Innovate the process of manufacturing
- Contribute to a more comfortable society with imaging and sensing technologies
- Contribute to peoples’ health and quality of life

Digital Manufacturing
Vision Systems/Robotics
Healthcare

Three areas for long-term growth


Reduction of greenhouse gases 2030 numerical targets
• Reduce emission of greenhouse gases from offices by 70% or more (compared to FY 2013)
• Shift to renewable energy for 30% of power used in business activities
Mid-/long-term capital allocation (FY2020/3 – 2024/3)

Focus resources on new fields to establish new core pillars of profit, without emphasizing short-term FCF

<table>
<thead>
<tr>
<th>New fields (Material processing business, areas of long-term growth)</th>
<th>Strategic Investments</th>
<th>R&amp;D</th>
<th>Capital Investment</th>
<th>Dividend &amp; Other</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Max 40%</td>
<td>10%</td>
<td>5%</td>
<td>10% or more Total return ratio 40% or more</td>
<td>10% or more Total return ratio 40% or more</td>
<td>10% or more</td>
</tr>
<tr>
<td>40%</td>
<td>35%</td>
<td>15%</td>
<td>10% or more</td>
<td>10% or more</td>
<td>100%</td>
</tr>
</tbody>
</table>

Existing fields

Return to shareholders

Scope: Funds on hand - working capital + 5-year cumulative operating CF (before deducting R&D)

Scope: Funds on hand - working capital + 5-year cumulative operating CF (before deducting R&D)
Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.